Neuroleptic malignant syndrome: Risk factors, pathophysiology, and treatment

Acta Neuropsychiatrica

Volumn 16, Issue 4, 2004, Pages 219-228

  Ananth, Jambur ^a,b   Aduri, Kamala ^a   Parameswarara, Sharath ^b   Gunatilake, Sarath ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b Metropolitan State Hospital   (United States)

Author keywords

Antipsychotic drugs and neuroleptic malignant syndrome; Neuroleptic malignant syndrome; Pathophysiology of neuroleptic malignant syndrome; Risk factors of neuroleptic malignant syndrome; Treatment of neuroleptic malignant syndrome

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; DANTROLENE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ELECTROLYTE; INFUSION FLUID; LEVODOPA; NEUROLEPTIC AGENT;

ADRENERGIC SYSTEM; ARTICLE; CATATONIA; DIAPHORESIS; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG INTOXICATION; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; ELECTROCONVULSIVE THERAPY; ELECTROLYTE BALANCE; FEVER; HEAT STROKE; HUMAN; HYPERSALIVATION; HYPERTENSION; INCONTINENCE; MALIGNANT HYPERTHERMIA; MENTAL HEALTH; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; NORADRENERGIC SYSTEM; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; RISK FACTOR; SYMPTOMATOLOGY; TACHYCARDIA; TACHYPNEA;

EID: 10844293663     PISSN: 09242708     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0924-2708.2004.00085.x     Document Type: Article

References (114)

1. DELAY J, PICHOT P, LEMPERIERE T et al. Un neuroleptique majeur non phenothiazine et non reserpine, l'haloperidol, dans le traitement des psychoses [Haloperidol, a nonphenothiazine, nonreserpine neuroleptic for the treatment of psychosis]. Annales Med-Psychologiques 1960;118:145-152.
2. KHAN M, FARVER D. Recognition, assessment and management of neuroleptic malignant syndrome. S D J Med 2000;53(9):395-400.
3. KECK PE JR, POPE HG, MCELROY SL. Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry 1987;144:1344-1366.
4. BERNARDI D, AMORE M, KECK P JR et al. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry 1998;44:748-754.
5. FAWCETT J. How do we keep our eyes open? Psychiatric Ann 2000;30:304.
6. CAROFF SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980;41:79-83.
7. SUSMAN VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q 2001;72(4):325-336.
8. ADDONIZIO G, SUSMAN VL, ROTH SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987;22:1004-1020.
9. SHALEV A, MUNITZ H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986;73:337-347.
10. ROSEBUSH P, STEWART T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989;146:717-725.
11. KECK PE, POPE HG, MCELROY SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 1991;148:880-882.
12. TORU M, MATSUDA O, MAKIGUCHI K, SUGANO K. Neuroleptic malignant syndrome-like state following a withdrawal of anti-parkinsonian drugs. J Nerv Ment Dis 1981;169:324-327.
13. FRIEDMAN JH, FEINBERG SS, FELDMAN RG. A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal. JAMA 1985;254:2792-2795.
14. YAMAWAKI Y, OGAWA N. Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease. Intern Med 1992;31:1298-1302.
15. GORDON PH, FRUCT SJ. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord 2001;16(5):960-974.
16. ITO T, SHIBATA K, WATANABE A et al. Neuroleptic malignant syndrome following withdrawal of amantadine in a patient with influenza: a encephalopathy. Eur J Pediatr 2001;160(6):401.
17. DE MONTIGNY C, COURNOYER G, MORISSETTE R, LANGLOIS R, CAILLE G. Lithium carbonate addition in tricyclic anti-depressant-resistant unipolar depression. Arch Gen Psychiatry 1983;40:1327-1334.
18. ASSIGN HJ, HEINEMANN F, LAUX G. Neuroleptic malignant syndrome under treatment with antidepressants? A critical review. Eur Arch Psychiatry Clin Neurosci 1998;248:231-239.
19. COHEN BM, HARRIS PQ, ALTESMAN RL et al. Neuroleptic as well as an antidepressant? Am J Psychiatry 1982;139:1165-1167.
20. THORNTON JE, STAHL SM. Case report of tardive dyskinesia and parkinsonism associated with amoxapine therapy. Am J Psychiatry 1984;141(5):704-705.
21. LYDIARD RB, GELENBERG AJ. Amoxapine: an antidepressant with some neuroleptic properties? A review of its chemistry, animal pharmacology and toxicology, human pharmacology and clinical efficacy. Pharmacotherapy 1981;1:163-178.
22. ANSSEAU M, REYNOLDS CF III, KUPFER DJ et al. Central dopaminergic and noradrenergic receptor blockade in a patient with neuroleptic malignant syndrome. J Clin Psychiatry 1986;47(6):320-321.
23. LANGLOW JR, ALARCON RD. Trimipramine-induced neuroleptic malignant syndrome after transient psychogenic polydipsia in one patient. J Clin Psychiatry 1989;50:144-145.
24. MADAKASIRA S. Amoxapine-induced neuroleptic malignant syndrome. Ann Pharmacother 1989;23:50-52.
25. SUMYOSHI A, OGUCHI T, TAKAHASHI A et al. Two cases of syndrome malin induced by tricyclic antidepressants. Seishin Shinkeigaku Zasshi 1982;36:461-462.
26. JUNE R, MERAJ Y, GOSSMAN W. Neuroleptic malignant syndrome associated with nortriptyline. Am J Emerg Med 1999;17:736-737.
27. AYDIN N, ANAC E, CAYKOYLU A et al. Neuroleptic malignant syndrome due to citalopram overdose. Can J Psychiatry 2000;45(10):941-942.
28. BALDESSARINI RJ, MARSH E. Fluoxetine and side effects. Arch Gen Psychiatry 1990;47:191-192.
29. CARTER CJ, PYCOCK CJ. Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats [proceedings]. Br J Pharmacol 1977;60(2):267P-268P.
30. CORRIGAN FM, COULTER F. Neuroleptic malignant syndrome, amitriptyline and thioridazine. Biol Psychiatry 1988;23:320-321.
31. VELAMOOR VR. NMS complicated by diazepam. Br J Psychiatry 1992;160:135-136.
32. MENZA MA, HARRIS D. Benzodiazepines and catatonia: an overview. Biol Psychiatry 1989;26(8):842-846.
33. LARNER AJ, SMITH SC, FARMER SF. Non-neuroleptic malignant' syndrome. J Neurol Neurosurg Psychiatry 1998;65(4):613.
34. SAMSON-FANG L, NORLIN C. Intrathecal baclofen withdrawal simulating neuroleptic malignant syndrome in a child with cerebral palsy. Dev Med Child Neurol 2000;42(8):561-565.
35. PARK-MATSUMOTO YC, TAZAWA T. Neuroleptic malignant syndrome associated with diphenhydramine and diprophyllin overdose in a depressed patient. J Neurol Sci 1999;162:108-109.
36. CHAN-TACK KM. Neuroleptic malignant syndrome due to promethazine. South Med J 1999;92:1017-1018.
37. EHARA H, MAEGAKI Y, TAKESHITA K. Neuroleptic malignant syndrome and methylphenidate. Pediatr Neurol 1998;19:299-301.
38. EDGAR J. Droperidol-induced neuroleptic malignant syndrome. Hosp Med 1999;60:448-450.
39. NIMMAGADDA SR, RYAN DH, ATKIN SL. Neuroleptic malignant syndrome after venlafaxine. Lancet 2000;355(9200):289-290.
40. CAROFF SN, MANN SC. Neuroleptic malignant syndrome. Psychopharmacol Bull 1988;24:25-29.
41. LAZARUS A, MANN SC, CAROFF SN. The neuroleptic malignant syndrome and related conditions. Washington, DC: American Psychiatric Press, 1989.
42. ITOH H, OHTSUKA N, OGITA K et al. Malignant neuroleptic syndrome: its present status in Japan and clinical problems. Seishin Shinkeigaku Zasshi 1977;31:565-576.
43. HARSCH HH. Neuroleptic malignant syndrome: physiological and laboratory findings in a series of nine cases. J Clin Psychiatry 1987;48:328-333.
44. PELORENO AL, LEVENSON JL, PANDURANGI AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv 1988;49(9):1163-1172.
45. TRELOAR AJ, CROOK MA, TUFF P et al. Iron status, movement disorders, and acute phase response in elderly psychotic patients. J Neurol Neurosurg Psychiatry 1994;57:208-210.
46. HERMESH H, MANOR I, SHILOH R et al. High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. J Clin Psychopharmacol 2002;22(3):252-256.
47. CAROFF SN, MANN SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77:185-202.
48. LEVENSEN JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142(10):1137-1145.
49. UEDA M, HAMAMOTO M, NAGAYAMA H et al. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. Neurology 1999;52:777-781.
50. AKPAFFIONG MJ, RUIZ P. Neuroleptic malignant syndrome: a complication of neuroleptics and cocaine abuse. Psychiatr Q 1991;62:299-309.
51. KOSTEN TR, KLEBER HD. Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome? Am J Drug Alcohol Abuse 1988;14:335-346.
52. DEUSCHL G, OEPEN G, HERMLE L. Neuroleptic malignant syndrome: observations on altered consciousness. Pharmacopsychiatry 1987;20:168-170.
53. OTANI K, HORIUCHI M, KONDO T et al. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry 1991;158:850-853.
54. LAZARUS AL, MOORE KE, SPINNER NB. Recurrent neuroleptic malignant syndrome associated with inv dup(15) and mental retardation. Clin Genet 1991;39:65-67.
55. KAWANISHI C, FURONO T, ONISHI H et al. Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity. Psychiatr Genet 2000;10(3):145-147.
56. 2 receptor gene in a patient with neuroleptic malignant syndrome. Am J Med Genet 1995;60:228-230.
57. 2 receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry 2001;158:1714-1716.
58. 2A receptor genes. Am J Psychiatry 1998;155:1275-1277.
59. KAWANISHI C, SHIMODA Y, FUZIMAKI J et al. Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. J Neurol Sci 1998;160(1):102-104.
60. CAROFF SN, MANN SC, LAZARUS A et al. Neuroleptic malignant syndrome: diagnostic issues. Psychiatric Ann 1991;21:130-147.
61. MOVES DG. Malignant hyperpyrexia caused by trimeprazine. Br J Anaesth 1973;45:1163-1164.
62. BOLES JM, LECAM B, MIALON P, PENNEC Y, GARRE M. Hyperthermie maligne des neuroleptiques: guérison rapide par le dantrolene. La Nouvelle Presse Medicale 1982;11:674.
63. YAMAWAKI S, YANO E, TERAKAWA N et al. On the results of a nationwide survey on neuroleptic malignant syndrome. Masui Sosei 1988;24(Suppl. 19):52-67.
64. YAMAWAKI S, YANO E, UCHITOMI Y et al. Analysis of 497 cases of neuroleptic malignant syndrome in Japan. Masui Sosei 1990;26:35-44.
65. PEIRIS DT, KURUPPUARACHCHI K, WEERASENA LP et al. Neuroleptic malignant syndrome without fever: a report of three cases. J Neurol Neurosurg Psychiatry 2000;69(2):277-278.
66. HAGGARTY JM, HUSNI M, PEAT C et al. Atypical neuroleptic malignant syndrome? Can J Psychiatry 1999;44(7):711-712.
67. MISIASZEK JJ, POTTER RL. Atypical neuroleptic malignant syndrome responsive to conservative management. Psychosomatics 1985;26:62-66.
68. LEE JWY. Catatonic and non-catatonic neuroleptic malignant syndrome. Aust N Z J Psychiatry 2000;34(5):877.
69. MANN SC, CAROFF SN, LAZARUS A. Pathogenesis of neuroleptic malignant syndrome. Psychiatric Ann 1991;21:175-180.
70. SAKKAS P, DAVIS JM, JANICAK PG et al. Drug treatment of neuroleptic malignant syndrome. Psychopharmacol Bull 1991;27:381-384.
71. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-293.
72. GREENBERG LB, GUJAVARTY K. The neuroleptic malignant syndrome: review and report of three cases. Compr Psychiatry 1985;26:63-70.
73. FINK M. Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry 1996;39:1-4.
74. TOLLEFSON G. A case of neuroleptic malignant syndrome: in vitro muscle comparison with malignant hyperthermia. J Clin Psychopharmacol 1982;2:266-270.
75. MIYATAKE R, IWANASHI K, MATSUSHITA M et al. No association between the neuroleptic malignant syndrome and mutations in the RYR1 gene associated with malignant hyperthermia. J Neurol Sci 1996;143:161-165.
76. FEIBEL JH, SCHIFFER RB. Sympathoadrenomedullary hyperactivity in the neuroleptic malignant syndrome: a case report. Am J Psychiatry 1981;138:1115-1116.
77. GURRERA RJ, ROMERO J. Sympathoadrenomedullary activity in neuroleptic malignant syndrome. Biol Psychiatry 1992;32:334-343.
78. GURRERA RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999;156:169-180.
79. MORRIS HH III, McCORMICK WF, REINARZ JA. Neuroleptic malignant syndrome. Arch Neurol 1980;37:462-463.
80. CONLON P. The spectrum concept of neuroleptic toxicity. Am J Psychiatry 1986;143:811.
81. DHIB-JALBUT S, HESSELBROCK R, MOURADIAN MM et al. Bromocriptine treatment of neuroleptic malignant syndrome. J Clin Psychiatry 1987;48:69-73.
82. PRICE DK, TURNBULL GJ, GREGORY RP et al. Neuroleptic malignant syndrome in a case of post-partum psychosis. Br J Psychiatry 1989;155:849-852.
83. GURRERA RJ, CHANG SS. Thermoregulatory dysfunction in neuroleptic malignant syndrome. Biol Psychiatry 1996;39:207-212.
84. KURLAN R, HAMILL R, SHOULSON I. Review: neuroleptic malignant syndrome. Clin Neuropharmacol 1984;7:109-120.
85. GOLDWASSER HD, HOOPER JF, SPEARS NM. Concomitant treatment of neuroleptic malignant syndrome and psychosis. Br J Psychiatry 1989;154:102-104.
86. HOFFMAN WH, CHODOROFF G, PIGGOT LR. Haloperidol and thyroid storm. Am J Psychiatry 1978;135:484-486 (correction, 135:762).
87. SCHIBUK M, SCHACTER D. A role for catecholamines in the pathogenesis of neuroleptic malignant syndrome. Can J Psychiatry 1986;31:66-69.
88. MURAO S, OGAWA N, ISHIBE Y et al. Neuroleptic malignant syndrome associated with droxidopa in a patient with striatonigral degeneration. Res Com Psychol Psychiatry Behav 1993;18:13-18.
89. KESHAVAN MS, STECKER J, KAMBHAMBATI RK. Creatinine kinase elevations with clozapine. Br J Psychiatry 1994;164:118-120.
90. GURRERA R, ROMERO J. Enzyme elevations in the neuroleptic malignant syndrome. Biol Psychiatry 1993;34:634-640.
91. PAPPAS NJ JR. Theoretical aspects of enzymes in diagnosis: why do serum enzymes change in hepatic, myocardial and other diseases? Clin Lab Med 1989;9:595-626.
92. LEW TY, TOLLEFSON G. Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry 1983;18(12):1441-1446.
93. KORNHUBER J, KORNHUBER ME. Presynaptic dopaminergic modulation of cortisol input into the striatum. Life Sci 1986;39:669-674.
94. WELLER M, KORNHUBER J. A rationale for NMDA receptor antagonist therapy of neuroleptic malignant syndrome. Med Hypotheses 1992;38:329-333.
95. 2+ release from intracellular stores in cultured cerebral cortical neurons. J Neurochem 1991;56:1075-1078.
96. OSMAN AA, KHURASANI MH. Lethal catatonia and neuroleptic malignant syndrome: a dopamine receptor shut-down hypothesis. Br J Psychiatry 1994;165:548-550.
97. FINK M, TAYLOR MA. The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 2001;251(Suppl. 1):1/8-1/13.
98. MANN SC, CAROFF SN, BLEIR HR et al. Lethal catatonia. Am J Psychiatry 1986;143:1374-1381.
99. NORTHOFF G, WENKE J, PFLUG B. Increase of serum creatinine phosphokinase in catatonia: an investigation in 32 acute catatonic patients. Psychol Med 1996;26:547-553.
100. ROSEBUSH PI, MAZUREK MF. Serum iron and neuroleptic malignant syndrome. Lancet 1991;338:149-151.
101. CASTILLO E, RUBIN RT, HALSBOER-TRACHSLER E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry 1989;146:324-328.
102. FRANCIS A, DIVADEENAM K, PETRIDES G. Advances in the diagnosis and treatment of catatonia. Convuls Ther 1997;12:259.
103. GURRERA RJ. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol 2002;25:1831-1893.
104. KECK PE JR, CAROFF SN, MCELROY SL. Neuroleptic malignant syndrome and malignant hyperthermia: end of a controversy? J Neuropsychiatry Clin Neurosci 1995;7:135-144.
105. SCHOU M. Long-lasting neurological sequelae after lithium intoxication. Acta Psychiatr Scand 1984;70:594-602.
106. SANSONE ME, ZIEGLER DK. Lithium toxicity: a review of neurologic complications. Clin Neuropharmacol 1985;8:242-248.
107. ADDONIZIO G. Rapid induction of extrapyramidal side effects with combined use of lithium and neuroleptics. J Clin Psychopharmacol 1985;5:296-298.
108. VELAMOOR VR, SWAMY GN, PARMAR RS et al. Management of suspected neuroleptic malignant syndrome. Can J Psychiatry 1995;40:545-550.
109. SCHEFTNER WA, SCULMAN RB. Treatment choice in neuroleptic malignant syndrome. Convuls Ther 1992;8:267-279.
110. NOLEN WA, ZWAAN WA. Treatment of lethal catatonia with electroconvulsive therapy and dantrolene sodium: a case report. Acta Psychiatr Scand 1990;82:90-92.
111. PENNATI A, SACCHETTI E, CALZERONI A. Dantrolene in lethal catatonia. Am J Psychiatry 1991;148:268.
112. KELFT EV, DEHERT M, HEYTENS L et al. Management of lethal catatonia with dantrolene sodium. Crit Care Med 1991;19:1449-1451.
113. PHILBRICK KL, RUMMANS TA. Malignant catatonia. J Neuropsychiatry 1994;6:1-13.
114. MANN SC, CAROFF SN, BLEIR HR et al. Electroconvulsive therapy of the lethal catatonia syndrome: case report and review. Convuls Ther 1990;6:239-247.